Immunogenomic analysis reveals LGALS1 contributes to the immune heterogeneity and immunosuppression in glioma
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
Mutualistic and dynamic communication between tumour cells and the surrounding microenvironment accelerates the initiation, progression, chemoresistance and immune evasion of glioblastoma (GBM). However, the immunosuppressive mechanisms of GBM has not been thoroughly elucidated to date. We enrolled six microenvironmental signatures to identify glioma microenvironmental genes. The functional enrichment analysis such as ssGSEA, ESTIMATE algorithm, Gene Ontology, Pathway analysis is conducted to discover the potential function of microenvironmental genes. In vivo and in vitro experiments are used to verify the immunologic function of LGALS1 in GBM. We screen eight glioma microenvironmental genes from glioma databases, and discover a key immunosuppressive gene (LGALS1 encoding Galectin‐1) exhibiting obviously prognostic significance among glioma microenvironmental genes. Gliomas with different LGALS1 expression have specific genomic variation spectrums. Immunosuppression is a predominate characteristic in GBMs with high expression of LGALS1. Knockdown of LGALS1 remodels the GBM immunosuppressive microenvironment by down regulating M2 macrophages and myeloid‐derived suppressor cells (MDSCs), and inhibiting immunosuppressive cytokines. Our results thus implied an important role of microenvironmental regulation in glioma malignancy and provided evidences of LGALS1 contributing to immunosuppressive environment in glioma and that targeting LGALS1 could remodel immunosuppressive microenvironment of glioma.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625
Inferring tumour purity and stromal and immune cell admixture from expression data
Yoshihara, K., Shahmoradgoli, M., Martínez, E., Vegesna, R., Kim, H., Torres-Garcia, W., Treviño, V., Shen, H., Laird, P. W., Levine, D. A., et al. (2013) · Nature Communications · doi:10.1038/ncomms3612 · Cited by 9,778 · cited 2×
“databases To investigate the underlying molecules involved in glioma microenvironment, we built six glioma microenvironment signatures containing mature vascular signature (Mature vascular), microvascular signature (Microvascular), hypoxia activation signature (Hypoxia activation),(21) tumour purity, stromal and immun…”
MethodVerhaak, R. G. W., Hoadley, K. A., Purdom, E., Wang, V., Qi, Y., Wilkerson, M. D., Miller, C. R., Ding, L., Golub, T., Mesirov, J. P., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2009.12.020 · Cited by 7,575 · cited 1×
“Next, we inspected the score level of glioma microenvironmental genes among the different molecular subtypes defined by the TCGA network.(22) The highest score level was observed in mesenchymal subtype in the TCGA (p = 1.”
MethodBindea, G., Mlecnik, B., Hackl, H., Charoentong, P., Tosolini, M., Kirilovsky, A., Fridman, W.-H., Pagès, F., Trajanoski, Z., & Galon, J. (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp101 · Cited by 6,280
TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells
Mariathasan, S., Turley, S. J., Nickles, D., Castiglioni, A., Yuen, K., Wang, Y., Kadel III, E. E., Koeppen, H., Astarita, J. L., Cubas, R., et al. (2018) · Nature · doi:10.1038/nature25501 · Cited by 5,400 · cited 1×
“immune evasion and attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells.(51) TGF-β facili-”
BackgroundStructural and functional features of central nervous system lymphatic vessels
Louveau, A., Smirnov, I., Keyes, T. J., Eccles, J. D., Rouhani, S. J., Peske, J. D., Derecki, N. C., Castle, D., Mandell, J. W., Lee, K. S., et al. (2015) · Nature · doi:10.1038/nature14432 · Cited by 4,413
Smoldering and polarized inflammation in the initiation and promotion of malignant disease
Balkwill, F., Charles, K. A., & Mantovani, A. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.02.013 · Cited by 1,769
The role of microglia and macrophages in glioma maintenance and progression
Hambardzumyan, D., Gutmann, D. H., & Kettenmann, H. (2016) · Nature Neuroscience · doi:10.1038/nn.4185 · Cited by 1,683 · cited 1×
“The poor prognosis is a product of the transformed cells communicating with vascular cells, stromal cells and infiltrating inflammatory cells in tumour microenvironment.(30) In the present study, through the TCGA, CGGA, Rembrandt and GSE16011 databases, eight microenvironmental genes were identified by statistical ana…”
BackgroundZhou, W., Ke, S. Q., Huang, Z., Flavahan, W., Fang, X., Paul, J., Wu, L., Sloan, A. E., McLendon, R. E., Li, X., et al. (2015) · Nature Cell Biology · doi:10.1038/ncb3090 · Cited by 940 · cited 1×
“In GBM, M2 could be recruited by periostin secreted by glioblastoma stem cells (GSC) to participate in malignant growth.(55) M2 macrophages produce TGF-β,(56) contributing to a tumour-supporting and immunosuppressive environment in tumours.”
BackgroundSchmittnaegel, M., Rigamonti, N., Kadioglu, E., Cassará, A., Wyser Rmili, C., Kiialainen, A., Kienast, Y., Mueller, H.-J., Ooi, C.-H., Laoui, D., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aak9670 · Cited by 582 · cited 1×
“VEGFA/VEGFR-targeting therapies could revert such an immunosuppressive state.(48,49) Evidence shows that GBM expresses high levels of CCL2 and could contain high numbers of CD14 cells.”
BackgroundMatarrese, P., Tinari, A., Mormone, E., Bianco, G. A., Toscano, M. A., Ascione, B., Rabinovich, G. A., & Malorni, W. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m409752200 · Cited by 182 · cited 1×
“Previous study showed that extracellular Galectin-1 encoded by LGALS1 could modulate the survival time of tumour-infiltrating T cells by enhancing Fas ligand-induced apoptosis.(32) Galectin-1 deficiency increased CD3+ lymphocytes, CD4+ lymphocytes, CD8+ lymphocytes and decreased CD4+ Foxp3+ Tregs in GBM.”
Cited by
Lin, H., Liu, C., Hu, A., Zhang, D., Yang, H., & Mao, Y. (2024) · Journal of Hematology & Oncology · doi:10.1186/s13045-024-01544-7 · Cited by 392
Molecular Mechanisms of Treatment Resistance in Glioblastoma
Ou, A., Yung, W. K. A., & Majd, N. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms22010351 · Cited by 269
Pharmacological targeting of the tumor–immune symbiosis in glioblastoma
Pang, L., Khan, F., Dunterman, M., & Chen, P. (2022) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2022.04.002 · Cited by 36
MR1 overexpression correlates with poor clinical prognosis in glioma patients
Kubica, P., Lara-Velazquez, M., Bam, M., Siraj, S., Ong, I., Liu, P., Priya, R., Salamat, S., Brutkiewicz, R. R., & Dey, M. (2021) · Neuro-Oncology Advances · doi:10.1093/noajnl/vdab034 · Cited by 20
Chen, J., Liu, Z., Fang, H., Su, Q., Fan, Y., Song, L., & He, S. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-05151-5 · Cited by 10
Metadata
- Authors
- Chen, Q., Han, B., Meng, X., Duan, C., Yang, C., Wu, Z., Magafurov, D., Zhao, S., Safin, S., Jiang, C., & Cai, J.
- Venue
- International Journal of Cancer
- Publisher
- Wiley
- Published
- 2019-01-22
- Volume
- 145
- Issue
- 2
- Pages
- 517-530
- ISSN
- 0020-7136 (ISSN-L)
- 1097-0215
- OpenAlex
- W2908536817
- Cited by
- 109
- References
- 11
- FWCI
- 6.37
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.